{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:53:28Z","timestamp":1740138808378,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004733","name":"Universidade de Macau","doi-asserted-by":"publisher","award":["MYRG2015-00008-FLL"],"award-info":[{"award-number":["MYRG2015-00008-FLL"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Asia Eur J"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10308-020-00569-0","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T03:03:43Z","timestamp":1582167823000},"page":"511-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A European proposal to regulate off-label prescription in China"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2181","authenticated-orcid":false,"given":"Vera L\u00facia","family":"Raposo","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"3","key":"569_CR1","first-page":"377","volume":"64","author":"R Abbott","year":"2014","unstructured":"Abbott R, Ayres I (2014) Evidence and extrapolation: mechanisms for regulating off-label uses of drugs and devices. Duke Law J 64(3):377\u2013435","journal-title":"Duke Law J"},{"key":"569_CR2","unstructured":"ANSM (AgenceNationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9) (2012) Temporary Recommendation for Use (RTUs) Principles and information on the methods used by the ANSM for establishment and implementation, available at ansm.sante.fr\/content\/download\/...\/RTU-english.pdf (last visited March 6, 2018)"},{"key":"569_CR3","unstructured":"Ask, M (2014) Drug Companies Oppose Moves to Reimburse Off-Label Medicine, The Wall Street Journal, available at at http:\/\/www.wsj.com\/articles\/drug-companies-oppose-moves-to-reimburse-off-label-medicine-1406287000 (last visited December 14, 2017)"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ejim.2015.08.008","volume":"26","author":"R Banzi","year":"2015","unstructured":"Banzi R, Gerardi C, Bertele V, Garattini S (2015) Approvals of drugs with uncertain benefit\u2013risk profiles in Europe. Eur J Intern Med 26:572\u2013584","journal-title":"Eur J Intern Med"},{"issue":"1","key":"569_CR5","first-page":"28","volume":"24","author":"LF Barrios Flores","year":"2014","unstructured":"Barrios Flores LF (2014) Responsabilidad por Uso Compasivo y Off-Label de Medicamentos. DS: Derecho y Salud 24(1):28\u201349","journal-title":"DS: Derecho y Salud"},{"issue":"4","key":"569_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jmp\/jhv016","volume":"40","author":"L Bian","year":"2015","unstructured":"Bian L (2015) Medical individualism or medical Familism? A critical analysis of China\u2019s new guidelines for informed consent: the basic norms of the documentation of the medical record. J Med Philos 40(4):371\u2013386. https:\/\/doi.org\/10.1093\/jmp\/jhv016","journal-title":"J Med Philos"},{"issue":"5","key":"569_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jmp\/jhq046","volume":"35","author":"X Chen","year":"2010","unstructured":"Chen X, Fan F (2010) The family and harmonious medical decision making: cherishing an appropriate Confucian moral balance. J Med Philos 35(5):573\u2013586. https:\/\/doi.org\/10.1093\/jmp\/jhq046","journal-title":"J Med Philos"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-015-0241-x","volume":"10","author":"Y Cui","year":"2015","unstructured":"Cui Y, Han J (2015) A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs. Orphanet J Rare Dis 10:28. https:\/\/doi.org\/10.1186\/s13023-015-0241-x","journal-title":"Orphanet J Rare Dis"},{"key":"569_CR9","doi-asserted-by":"publisher","unstructured":"Detela G, Lodge A (2019) EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation. Mol Ther Methods Clin Dev 13. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.010","DOI":"10.1016\/j.omtm.2019.01.010"},{"issue":"3","key":"569_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1748-720X.2009.00408.x","volume":"37","author":"R Dresser","year":"2009","unstructured":"Dresser R, Frader J (2009) Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics 37(3):476\u2013486","journal-title":"J Law Med Ethics"},{"issue":"2","key":"569_CR11","first-page":"26","volume":"21","author":"L Du","year":"2013","unstructured":"Du L, Rachul C (2013) A brief review on informed consent Laws in China. Health Law Review 21(2):26\u201332","journal-title":"Health Law Review"},{"key":"569_CR12","doi-asserted-by":"crossref","unstructured":"Eguale T, Buckeridge D, Winslade N, Benedetti A, Hanley J, Tamblyn R (2012) Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Archives Internal Medicine 172(10):781\u2013788","DOI":"10.1001\/archinternmed.2012.340"},{"key":"569_CR13","unstructured":"EMA (European Medicines Agency) (2002) Concept Paper on Conduct of Pharmacovigilance for Medicines Used by Children, available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003765.pdf (last visited January April 3, 2018)"},{"key":"569_CR14","unstructured":"EMA (European Medicines Agency) (2004) Evidence of Harm from Off-Label or Unlicensed Medicines in Children, EMEA\/126327\/2004, available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2009\/10\/WC500004021.pdf (last visited April 3, 2018)"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/annonc\/mdm517","volume":"18","author":"ESMO","year":"2007","unstructured":"ESMO (2007) The off-label of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 18:1923\u20131925","journal-title":"Ann Oncol"},{"key":"569_CR16","unstructured":"European Commission (2013) Report from the Commission to the Council on the Basis of Member States' Reports on the Implementation of the Council Recommendation (2009\/C 151\/01) on Patient Safety, Including the Prevention and Control of Healthcare-Associated Infections (2013\/2022(INI)), available at http:\/\/www.europarl.europa.eu\/oeil\/popups\/printficheglobal.pdf?id=618835&l=en (last visited March 28, 2018)"},{"key":"569_CR17","unstructured":"First Word (2011) MSL-KOL Engagement: Ensuring Compliance, at http:\/\/themsls.org\/Resources\/Documents\/Summary-MSL%20and%20KOL%20Regulatory%20Compliance.pdf (last visited June 20, 2017)"},{"key":"569_CR18","volume-title":"Legal and Forensic Medicine1617","author":"M Francisco","year":"2013","unstructured":"Francisco M (2013) Off Licence Use of Medications - Off-Label \u2013 Off Law? In: Beran RG (ed) Legal and Forensic Medicine 1617"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jep.12673","volume":"23","author":"N Ghinea","year":"2017","unstructured":"Ghinea N, Kerridge I, Little M, Lipworth W (2017) Challenges to the validity of using medicine labels to categorize clinical behavior: an empirical and normative critique of \u201coff-label\u201d prescribing. J Eval Clin Pract 23:574\u2013581","journal-title":"J Eval Clin Pract"},{"key":"569_CR20","doi-asserted-by":"crossref","unstructured":"Gillick MR (2009) Controlling off-label medication use. Annals Internal Medicine 150(5):344\u2013347","DOI":"10.7326\/0003-4819-150-5-200903030-00108"},{"issue":"1","key":"569_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"AK Hall","year":"2014","unstructured":"Hall AK, Carlson MR (2014) The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res 3(1):1\u20137","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"569_CR22","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1136\/adc.2004.058867","volume":"90","author":"P Hill","year":"2005","unstructured":"Hill P (2005) Off Licence and off label prescribing in children: litigation fears for physicians. Arch Dis Child 90(1):i17\u2013i18. https:\/\/doi.org\/10.1136\/adc.2004.058867","journal-title":"Arch Dis Child"},{"key":"569_CR23","unstructured":"Irish Patients\u2019 Association (2012) Patient Safety, Patients\u2019 Rights and Off-Label Prescribing, available at http:\/\/irishpatients.ie\/news\/wp-content\/uploads\/2012\/03\/IPA_Off_Label_WEBr-1.pdf (last visited April 16, 2018)"},{"key":"569_CR24","unstructured":"J\u00f6rg A (2007) Medicinal products during pregnancy and lactation \u2013 an issue of risk management, at http:\/\/www.dgra.de\/studiengang\/pdf\/master_joerg_a.pdf (last visited march 5, 2018)"},{"issue":"4","key":"569_CR25","doi-asserted-by":"publisher","first-page":"e1000431","DOI":"10.1371\/journal.pmed.1000431","volume":"8","author":"A Kesselheim","year":"2011","unstructured":"Kesselheim A, Mello MM, Studdert DM (2011) Strategies and practices in off-label Marketing of Pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 8(4):e1000431. https:\/\/doi.org\/10.1371\/journal.pmed.1000431","journal-title":"PLoS Med"},{"key":"569_CR26","doi-asserted-by":"crossref","unstructured":"Langerov\u00e1 P, Vrtal J and Urb\u00e1nek K (2014) Incidence of Unlicensed and off-Label Prescription in Children, Italian Journal of Pediatrics, 40, 12, at http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3915231\/pdf\/1824-7288-40-12.pdf (last visited February 14, 2018)","DOI":"10.1186\/1824-7288-40-12"},{"key":"569_CR27","unstructured":"L'Ecluse P, Longeval C and T'Syen K (2013) Off-label use of medicinal products and product liability, available at athttp:\/\/us.practicallaw.com\/8-525-5657 (last visited January 15, 2018)"},{"key":"569_CR28","doi-asserted-by":"crossref","unstructured":"Lenk C, Duttge G (2014) Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 10(1):537\u2013546","DOI":"10.2147\/TCRM.S40232"},{"key":"569_CR29","unstructured":"Li, CH and Huang H (2016) China - Pharmaceutical Advertising 2016, Published: 14\/06\/2016, at https:\/\/www.iclg.co.uk\/practice-areas\/pharmaceutical-advertising\/pharmaceutical-advertising-2016\/china#chaptercontent2 (last visited March 24, 2018)"},{"key":"569_CR30","doi-asserted-by":"crossref","unstructured":"Liu ZH (2013) Children forced o take adult medication. China daily, Dec 25, 2013, at http:\/\/www.chinadaily. Com.Cn\/life\/2013-12\/25\/content_17195142. Htm (last visited January 25, 2018)","DOI":"10.5136\/lifesupport.25.25"},{"issue":"2","key":"569_CR31","first-page":"189","volume":"68","author":"F Ma","year":"2013","unstructured":"Ma F, Lou N (2013) Chinese regulation of off-label use of drugs. Food Drug Law J 68(2):189\u2013200","journal-title":"Food Drug Law J"},{"key":"569_CR32","unstructured":"Maglio I (2013) Responsabilidad M\u00e9dica en la Prescripcion de F\u00e1rmacos en Indicaciones no Aprobadas (Uso Off Label), Biblioteca Virtual Noble, available at http:\/\/www.noble-arp.com\/src\/img_up\/30102013.0.pdf (last visited March 8, 2018)"},{"issue":"1","key":"569_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00228-011-1097-1","volume":"68","author":"J Mason","year":"2012","unstructured":"Mason J, Pirmohamed M, Nunn T (2012) Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 68(1):21\u201328. https:\/\/doi.org\/10.1007\/s00228-011-1097-1","journal-title":"Eur J Clin Pharmacol"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMhle0807695","volume":"360","author":"MM Mello","year":"2009","unstructured":"Mello MM, Studdert DM, Brennan TA (2009) Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med 360:1557\u20131566","journal-title":"N Engl J Med"},{"key":"569_CR35","doi-asserted-by":"crossref","unstructured":"Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, Giaquinto C, Knibbe CA, Sturkenboom MC, Ghaleb MA, Ceci A (2008) Defining Off-Label and Unlicensed Use of Medicines for Children: Results of a Delphi Survey. Pharmacol Res:316\u2013322","DOI":"10.1016\/j.phrs.2008.09.007"},{"key":"569_CR36","unstructured":"Obermann S (2013) Off-label use of medicines \u2013 general aspects, challenges and strategies (Wissenschaftliche Pr\u00fcfungsarbeit zur Erlangung des Titels, \u2212 Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen Fakult\u00e4t der Rheinischen Friedrich-Wilhelms-Universit\u00e4t Bonn), at http:\/\/dgra.de\/media\/pdf\/studium\/masterthesis\/master_obermann_s.pdf. Accessed 10 Feb 2020"},{"key":"569_CR37","unstructured":"Pacific Bridge Medical (2014) China Regulatory and Market Access Pharmaceutical Report, available at http:\/\/www.pacificbridgemedical.com\/wp-content\/uploads\/2015\/04\/China-Regulatory-and-Market-Access-Pharmaceutical-Report-2014.pdf (last visited March 15, 2018)"},{"key":"569_CR38","unstructured":"Parzeller, Markus et al. (2007) Patient Information and Informed Consent before and after Medical Intervention, 104(9) Dtsch Arztebl A576"},{"issue":"2","key":"569_CR39","first-page":"217","volume":"32","author":"CS Paula","year":"2011","unstructured":"Paula CS, Souza MN, Miguel MD, Miguel OG (2011) Uso Off-Label de Medicamentos em Crian\u00e7as e Adolescentes. Revista de Ci\u00eancias Farmac\u00eauticas B\u00e1sica e Aplicada 32(2):217\u2013223","journal-title":"Revista de Ci\u00eancias Farmac\u00eauticas B\u00e1sica e Aplicada"},{"key":"569_CR40","unstructured":"Plate V (2009) The impact of off-label, compassionate and unlicensed use on health care Laws in preselected countries (dissertation zur Erlangung des Doktorgrades (Dr. rer. Nat.) der Mathematisch-Naturwissenschaftlichen Fakult\u00e4t der Rheinischen Friedrich-Wilhelms-Universit\u00e4t Bonn), available at http:\/\/hss.ulb.uni-bonn.de\/2009\/1936\/1936.pdf (last visited January 28, 2018)"},{"key":"569_CR41","unstructured":"Raposo VL (2013) Do Ato M\u00e9dico ao Problema Jur\u00eddico (Breves Notas sobre o Acolhimento da Responsabilidade M\u00e9dica Civil e Profissional na Jurisprud\u00eancia Nacional). Coimbra: Coimbra Editora"},{"issue":"21","key":"569_CR42","first-page":"35","volume":"11","author":"VL Raposo","year":"2014","unstructured":"Raposo VL (2014) Prescri\u00e7\u00e3o Off-Label de Medicamentos e de Dispositivos M\u00e9dicos. Lex Medicinae 11(21):35\u201376","journal-title":"Lex Medicinae"},{"key":"569_CR43","doi-asserted-by":"publisher","unstructured":"Raposo VL (2020) The CJEU\u2019s ruling in the Novartis Farma case: Money, health and medicines. Maastricht Journal of European and Comparative Law. https:\/\/doi.org\/10.1177\/1023263X20904228","DOI":"10.1177\/1023263X20904228"},{"key":"569_CR44","unstructured":"Repucci N (2011) An examination of off-label marketing and promotion: settlements, Issues, and Trends. J Health Care Compliance:15\u201321"},{"key":"569_CR45","unstructured":"Riley J Jr, Basilius PA (2007) Physicians\u2019 liability for off-label prescriptions. Hematol Oncol News Issues:24\u201327"},{"key":"569_CR46","doi-asserted-by":"crossref","unstructured":"Rocchi F, Paolucci P, Ceci A, Rossi P. (2010) The European pediatric legislation: benefits and perspectives, Italian journal of pediatrics 1, 36-56, available at http:\/\/www.ijponline.net\/content\/36\/1\/56 (last visited march 13, 2016)","DOI":"10.1186\/1824-7288-36-56"},{"key":"569_CR47","unstructured":"Royal College of Paediatrics and Child Health (2010) The Use of Unlicensed Medicines or Licensed Medicines for Unlicensed Applications in Paediatric Practice, 29th October 2010, at http:\/\/www.rcpch.ac.uk\/system\/files\/protected\/page\/RCPCH%20Revised%20Statement%20on%20Unlicensed%20Medicines%20October%202010%20FINAL_0.pdf (last visited June 10, 2017)"},{"key":"569_CR48","unstructured":"Schoonderbeek C and Lisman J (2007\/2008) Off-label use of medicinal products: a legal update, life sciences 25-31, available at www.practicallaw.com\/7-378-8639 (last visited January 16, 2018)"},{"key":"569_CR49","doi-asserted-by":"crossref","unstructured":"Stafford R (2008) Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med 358(14):1427\u20131429","DOI":"10.1056\/NEJMp0802107"},{"key":"569_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","volume":"145","author":"MA Steinman","year":"2006","unstructured":"Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145:284\u2013293","journal-title":"Ann Intern Med"},{"issue":"22","key":"569_CR51","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2146\/ajhp070681","volume":"66","author":"C Stucki","year":"2009","unstructured":"Stucki C, Sautter AM, Favet J, Bonnabry P (2009) Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulations on end-product quality. Am J Health Syst Pharm 66(22):2032\u20132036. https:\/\/doi.org\/10.2146\/ajhp070681","journal-title":"Am J Health Syst Pharm"},{"key":"569_CR52","unstructured":"Tiwary D (2003) Off-label use of prescription drugs should be regulated by the FDA, Harvard law school, available at https:\/\/dash.harvard.edu\/bitstream\/handle\/1\/8852151\/FDLI_FDA_off_label_regulation.pdf?sequence=1 (last visited April 13, 2018)"},{"issue":"2","key":"569_CR53","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson N (2015) Thalidomide-induced Teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105(2):140\u2013156. https:\/\/doi.org\/10.1002\/bdrc.21096","journal-title":"Birth Defects Res C Embryo Today"},{"key":"569_CR54","unstructured":"Vrueh R, Baekelandt ERF and Haan, JMH (2013) Background Paper 6.19 Rare Diseases, Update on 2004 Leufken, 2013, at http:\/\/www.who.int\/medicines\/areas\/priority_medicines\/BP6_19Rare.pdf (last visited July 10, 2017)"},{"key":"569_CR55","unstructured":"Wang K (2015) Unanswered questions: China's new Pharma advertising rule, at http:\/\/www.law360.com\/articles\/695056\/unanswered-questions-china-s-new-pharma-advertising-rule (last visited January 12, 2018)"},{"key":"569_CR56","unstructured":"Working Group of NSW Tag Inc (2003) Off-label Use of Registered Medicines and Use of Medicines under the Personal Importation Scheme in NSW Public Hospitals: A Discussion Paper, September 2003, available at http:\/\/www.ciap.health.nsw.gov.au\/nswtag\/documents\/publications\/other-docs\/off-label-use-sept-2003.pdf (last visited December 5, 2017)"},{"key":"569_CR57","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00228-014-1729-3","volume":"70","author":"H Wu","year":"2014","unstructured":"Wu H, Wu G (2014) Strategy to address innovative off-label medication use in China. Eur J Clin Pharmacol 70:1271\u20131273. https:\/\/doi.org\/10.1007\/s00228-014-1729-3","journal-title":"Eur J Clin Pharmacol"},{"key":"569_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13023-015-0361-3","volume":"10","author":"L Yang","year":"2015","unstructured":"Yang L, Su C, Lee AM, Bai HX (2015) Focusing on rare diseases in China: are we there yet? Orphanet J Rare Dis 10:142. https:\/\/doi.org\/10.1186\/s13023-015-0361-3","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"569_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jebm.12017","volume":"6","author":"L Zhang","year":"2013","unstructured":"Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L, Chen M, Lv J, Yang C (2013) Pediatric off-label drug use in China: risk factors and management strategies. J Evid Based Med 6(1):4\u201318. https:\/\/doi.org\/10.1111\/jebm.12017","journal-title":"J Evid Based Med"},{"key":"569_CR60","doi-asserted-by":"crossref","unstructured":"Zheng Z and Xu F (2010) Chinese pharmacists propose patient consent for unlabeled use of medications, the journal of managed care pharmacy, 16(8), 640, available at http:\/\/www.amcp.org\/data\/jmcp\/640.pdf (last visited January 15, 2018)","DOI":"10.18553\/jmcp.2010.16.8.640"}],"container-title":["Asia Europe Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10308-020-00569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10308-020-00569-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10308-020-00569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T19:50:29Z","timestamp":1613764229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10308-020-00569-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s10308-020-00569-0","relation":{},"ISSN":["1610-2932","1612-1031"],"issn-type":[{"type":"print","value":"1610-2932"},{"type":"electronic","value":"1612-1031"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"24 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}